| Literature DB >> 34532465 |
Enjun Zhu1, Chen Zhang2, Shengwei Wang1, Xiaohai Ma3, Yongqiang Lai1.
Abstract
BACKGROUND: The factors that associated with the response of moderate ischemic mitral regurgitation (IMR) to isolated coronary artery bypass grafting (CABG) remain unclear. This study aims to evaluate whether left ventricular (LV) myocardial scar assessed by cardiovascular magnetic resonance (CMR) is associated with the outcome of moderate IMR after isolated CABG.Entities:
Keywords: Coronary artery disease (CAD); cardiovascular magnetic resonance (CMR); ischemic mitral regurgitation (IMR); myocardial scar
Year: 2021 PMID: 34532465 PMCID: PMC8422129 DOI: 10.21037/atm-21-3622
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Flowchart. CAD, coronary artery disease; IMR, ischemic mitral regurgitation; CMR, cardiovascular magnetic resonance; CABG, coronary artery bypass grafting.
Figure 2LGE-CMR detected myocardial scar. (A) A typical LGE image obtained by CMR in the short-axis view; (B) myocardial scar (yellow) is detected after outlining the endocardium (red) and epicardium (green) in one patient. LGE, late gadolinium enhancement; CMR, cardiovascular magnetic resonance.
Baseline and perioperative characteristics
| Variables | Improved (n=24) | Unimproved (n=22) | P |
|---|---|---|---|
| Age, years | 57.4±13.7 | 58.6±7.6 | 0.72 |
| Males, % | 20 (83.3%) | 17 (77.3%) | 0.61 |
| Body mass index, kg/m2 | 25.8±2.7 | 25.2±3.8 | 0.52 |
| NYHA class | 2.3±0.7 | 2.4±0.7 | 0.59 |
| Hypertension | 15 (62.5%) | 11 (50.0%) | 0.39 |
| Hyperlipidemia | 10 (41.7%) | 6 (27.3%) | 0.31 |
| Diabetes mellitus | 10 (41.7%) | 6 (27.3%) | 0.31 |
| History of smoking | 12 (50.0%) | 13 (59.1%) | 0.54 |
| Heart rate, b/min | 71.4±11.6 | 73.7±13.1 | 0.53 |
| Atrial fibrillation | 1 (4.2%) | 1 (4.5%) | 0.95 |
| PMI | 7 (29.2%) | 6 (27.3%) | 0.89 |
| Total scar | 18.0±9.5 | 30.8±11.2 | <0.001 |
| Inferior wall infarction | 13 (54.2%) | 16 (72.7%) | 0.19 |
| Graft vessels, n | 3.3±0.6 | 3.3±0.5 | 0.91 |
| Hospital stay, days | 12.5±4.5 | 12.4±3.2 | 0.91 |
| Ventilation time, min | 22.8±19.3 | 28.2±19.0 | 0.35 |
NYHA, New York Heart Association; PMI, papillary muscle infarction.
Baseline and latest follow-up data
| Variables | Improved (n=24) | Unimproved (n=22) | P |
|---|---|---|---|
| LVEDV, mL | |||
| Baseline | 139.8±35.7 | 158.5±36.2 | 0.08 |
| Follow-up | 126.2±36.1 | 156.3±45.4 | 0.01 |
| LVESV, mL | |||
| Baseline | 72.7±31.7† | 87.0±36.8 | 0.16 |
| Follow-up | 54.8±28.0† | 86.0±35.8 | 0.002 |
| LVEF, % | |||
| Baseline | 50.0±11.6 | 43.0±13.5 | 0.06 |
| Follow-up | 51.0±12.6 | 41.0±13.2 | 0.01 |
†, LVESV at 12-month follow-up was significantly reduced compared with baseline in the improved group. LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction.
Results of univariate and multivariate logistic regression analyses to predict the improvement of IMR
| Variable | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| Age, years | 0.99 (0.94–1.04) | 0.72 | – | – | |
| Male gender | 1.47 (0.34–6.36) | 0.61 | – | – | |
| Body mass index, kg/m2 | 1.06 (0.89–1.28) | 0.51 | – | – | |
| LVEF | 1.01 (0.89–1.10) | 0.06 | – | – | |
| LVEDV | 0.99 (0.94–1.06) | 0.09 | – | – | |
| LVESV | 1.00 (0.94–1.07) | 0.16 | – | – | |
| Total scar | 0.89 (0.83–0.96) | 0.001 | 0.89 (0.83–0.96) | 0.001 | |
| PMI | 0.84 (0.15–4.66) | 0.89 | – | – | |
| Inferior wall infarction | 2.58 (0.48–14.00) | 0.19 | – | – | |
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; PMI, papillary muscle infarction.
Figure 3The Kaplan-Meier curve estimating the survival of patients in the unimproved group (yellow) and the improved group (blue) (log-rank test, P=0.46).
Long-term clinical outcome
| Variables | Improved (n=24) | Unimproved (n=22) | P |
|---|---|---|---|
| NYHA class | 1.8±0.7 | 2.4±0.7 | 0.01 |
| All-cause mortality, n (%) | 2 (7.6) | 4 (18.2) | 0.46 |
| Major adverse cardiac events, n (%) | 2 (7.6) | 8 (36.4) | 0.03 |
NYHA, New York Heart Association.